

Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes –  
A Review of the 2022 ASCO Annual Meeting and EHA Congress

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following molecules is targeted by the monoclonal antibody sabatolimab under investigation for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)?
  - TIM-3
  - TP53
  - RUNX1
  - FLT3
- The Phase III QuANTUM-First trial demonstrated a statistically significant benefit in relapse-free survival and overall survival in which of the following patients receiving quizartinib with standard induction chemotherapy and consolidation followed by single-agent quizartinib?
  - Patients with newly diagnosed disease and no targetable mutations
  - Patients with newly diagnosed disease and  $\geq 3\%$  FLT3-ITD allelic frequency
  - Patients under age 60 with heavily pretreated disease and  $\geq 3\%$  FLT3-ITD allelic frequency
  - Patients with heavily pretreated disease and concurrent FLT3-ITD and IDH1 mutations
- Which of the following best describes observations of cytokine release syndrome (CRS) observed in preliminary clinical investigation of CD33 CAR-NK cells?
  - CRS has not been observed with CD33 CAR NK-cell therapy
  - CRS occurs in ~20% of patients and all events are Grade 1-2
  - CRS occurs in >50% of patients and all events are Grade 1-2
  - CRS occurs in ~20% of patients and most events are Grade 3-4
  - CRS occurs in >50% of patients and most events are Grade 3-4
- Which of the following was the most commonly observed any-grade adverse event, regardless of causality, in the 5F9005 trial evaluating magrolimab with azacitidine for higher-risk MDS?
  - Headache
  - Rash
  - Central serous retinopathy
  - Constipation
- The Phase II STIMULUS-AML1 trial is currently evaluating sabatolimab in combination with which of the following agents for patients with newly diagnosed AML who are not eligible for chemotherapy?
  - CPX-351
  - Magrolimab
  - Venetoclax/azacitidine
  - Venetoclax/quizartinib/decitabine